Lotus Eye Hospital confirms FY26 results in routine filing
The board formally approved audited financial results for Q4 and FY26. This filing confirms data already disclosed to the market.
— 2 earlier stories on Lotus Eye Hospital And Institute Ltd. →Mkt cap₹260 cr
ROE1.23%
Debt / eq.0.01
FY26 Fiscal year for which audited results were formally approved.
What's new
- The board formally approved audited financial results for Q4 and FY26.
- This filing confirms previously disclosed earnings data.
- No new information or surprises were contained in this document.
Why this matters
This is a procedural confirmation of previously released data. It adds no new information for investors to digest.
What we're watching
- Future capital expenditure plans mentioned in the rationale.
- Any further commentary on the earnings decline.
- Operational updates in upcoming quarterly disclosures.
The full read
Lotus Eye Hospital and Institute has formally approved its audited financial results for Q4 and FY26.
This filing is a routine confirmation of data already disclosed to the market. There are no surprises or new disclosures in this document. The company previously reported an earnings decline and outlined capital expenditure plans, which remain the primary focus for investors. This filing adds nothing to that narrative.
It is a formality.
Questions answered
- Does this filing change the previously reported FY26 earnings?
- No. This is a routine confirmation of audited results that were already disclosed to the market.
- What period does this filing cover?
- It covers the audited financial results for the fourth quarter and the full fiscal year 2026.
- Are there any new surprises in this document?
- No. The filing is a formal board approval of existing data and contains no new information.
Mentioned: Lotus Eye Hospital And Institute Ltd.
Company snapshot
Lotus Eye Hospital And Institute Ltd.
Hospitals
₹263 cr
Latest quarter · Mar 2026
Sales₹14 cr
Net profit−₹0 cr
Op. margin+3.5%
EPS−₹0.15
Strength & growth
Debt / equity0.01×
Current ratio1.56×
Sales CAGR+5.6%
EPS CAGR−2.0%
Story so far
All notes on LOTUSEYE →- 26 May 2026 · 8:51 PM IST Lotus Eye Hospital confirms FY26 results in routine filing
- 52d ago Lotus Eye Hospital swings to loss as expansion costs mount
- 52d ago Lotus Eye Hospital swings to loss as expansion costs mount